Altimmune Revenue and Competitors
Estimated Revenue & Valuation
- Altimmune's estimated annual revenue is currently $7.5M per year.
- Altimmune's estimated revenue per employee is $110,294
- Altimmune's total funding is $51.4M.
Employee Data
- Altimmune has 68 Employees.
- Altimmune grew their employee count by 13% last year.
Altimmune's People
| Name | Title | Email/Phone |
|---|---|---|
1 | COO | Reveal Email/Phone |
2 | VP, Commercial Strategy and Portfolio Development | Reveal Email/Phone |
3 | Head Safety and Pharmacovigilance | Reveal Email/Phone |
4 | VP Clinical Operations | Reveal Email/Phone |
5 | VP, Product Development | Reveal Email/Phone |
6 | VP Regulatory Affairs | Reveal Email/Phone |
7 | VP, Quality and Compliance Management | Reveal Email/Phone |
8 | VP, Biostatistics and Data Management | Reveal Email/Phone |
9 | VP, Finance | Reveal Email/Phone |
10 | Director Financial Reporting | Reveal Email/Phone |
Altimmune Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4.2M | 122 | -22% | $52.7M | N/A |
What Is Altimmune?
Altimmune is a clinical stage immunotherapeutic biotechnology company located in Montgomery County, MD with additional operating sites in London, UK and Strasbourg, France. By leveraging the complementary attributes of its two innovative vaccine delivery platforms, RespirVec™ and Densigen™, Altimmune is able to rationally design and rapidly develop immunotherapeutic products tailored to address the a wide range of disease indications including acute respiratory infections, chronic viral infections and cancer with fundamental advantages over competing products.
keywords:N/A
$51.4M
Total Funding
68
Number of Employees
$7.5M
Revenue (est)
13%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Altimmune News
Altimmune, Inc. (NASDAQ:ALT) Short Interest Update. Posted by admin on Apr 16th, 2022. Share on Twitter Share on Facebook Share on LinkedIn Share on...
Altimmune used to be an infectious disease player. After a lot of upheavals last year, it has now moved on to obesity, NASH and NAFLD.
Altimmune is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of...
GAITHERSBURG, Md. and BASEL, Switzerland, March 12, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it has expanded its previously-announced AdCOVID manufacturing collaboration with Lonza. Under the expanded agreement, Lonz ...
GAITHERSBURG, Md., March 08, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the management team will present during a fireside chat at the H.C. Wainwright Global Life Sciences Conference, being held Mar 9-10, 20 ...
Other Companies in Gaithersburg
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $10.5M | 68 | 0% | N/A |
#2 | $6.4M | 70 | 6% | N/A |
#3 | $17M | 70 | 4% | N/A |
#4 | $14.1M | 70 | 4% | N/A |
#5 | $20.9M | 72 | 6% | N/A |